Phase 1 Evaluation of EXL01 Safety and Target Engagement in Steroid-Induced Remission Maintenance for Mild to Moderate Crohn’s Disease

The primary objective of this Phase 1 study is to evaluate the **safety** and target engagement of EXL01 in maintaining a steroid-induced clinical response or remission in patients with mild to moderate **Crohn's Disease**. This is clinically relevant as it aims to assess the potential of EXL01 to sustain therapeutic benefits achieved through steroid treatment, which is crucial for long-term disease management and improving patient outcomes.

The clinical trial involves participants diagnosed with **Crohn's Disease**. The study population includes both male and female subjects, with an age range that encompasses both adults and adolescents. The trial population selection criteria include a focus on vulnerable populations, although specific inclusion or exclusion criteria are not provided. The sponsor has not disclosed the total number of participants involved in the study. Information regarding lifestyle considerations such as diet, physical activity, or habits is not available. The trial aims to gather data from a diverse group of individuals to ensure comprehensive insights into the disease's impact across different demographics.

The clinical trial is a **Phase 1** study designed to evaluate the safety and target engagement of EXL01 in maintaining steroid-induced clinical response or remission in patients with mild to moderate **Crohn's Disease**. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from February 25, 2022, to February 1, 2025, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor safety, efficacy, and any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the long-term effects of the intervention.

The expected length of participant involvement in the trial is approximately three years, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse events, fail to comply with study protocols, or withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure participant safety and data integrity.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date was February 25, 2022, with an anticipated end date of February 1, 2025. Although specific primary and secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage parameters, with preliminary efficacy assessments often included. The trial will likely involve regular monitoring and data collection at predetermined intervals to evaluate the intervention's impact on the targeted condition. The analysis will be conducted using standard statistical methods appropriate for early-phase trials, ensuring that any observed effects are accurately interpreted within the context of the study's objectives.